SK9552003A3 - New salt of thiazolidinedione and its polymorphs as antidiabetic agents and method for obtaining them - Google Patents
New salt of thiazolidinedione and its polymorphs as antidiabetic agents and method for obtaining them Download PDFInfo
- Publication number
- SK9552003A3 SK9552003A3 SK955-2003A SK9552003A SK9552003A3 SK 9552003 A3 SK9552003 A3 SK 9552003A3 SK 9552003 A SK9552003 A SK 9552003A SK 9552003 A3 SK9552003 A3 SK 9552003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- compound
- solution
- polymorph
- solvent
- preparing
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 12
- 239000003472 antidiabetic agent Substances 0.000 title claims description 4
- 229940125708 antidiabetic agent Drugs 0.000 title claims description 4
- 150000003839 salts Chemical class 0.000 title abstract description 8
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 title description 9
- 229940123464 Thiazolidinedione Drugs 0.000 title description 3
- 238000011282 treatment Methods 0.000 claims abstract description 9
- -1 6-methoxy-pyrimidin-4-yl Chemical group 0.000 claims abstract description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 6
- 238000011321 prophylaxis Methods 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 159000000000 sodium salts Chemical class 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 235000019441 ethanol Nutrition 0.000 claims description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 5
- 238000002441 X-ray diffraction Methods 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 5
- 201000001421 hyperglycemia Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000012047 saturated solution Substances 0.000 claims description 5
- NVIVKAGMJLHDTR-UHFFFAOYSA-N 5-[[4-[2-[(6-methoxypyrimidin-4-yl)-methylamino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=NC(OC)=CC(N(C)CCOC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)=N1 NVIVKAGMJLHDTR-UHFFFAOYSA-N 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 239000003791 organic solvent mixture Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229910001415 sodium ion Inorganic materials 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 201000001431 Hyperuricemia Diseases 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 230000002124 endocrine Effects 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 229940100389 Sulfonylurea Drugs 0.000 claims description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 2
- 229940125388 beta agonist Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 229940122355 Insulin sensitizer Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 235000014121 butter Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 2
- 230000004075 alteration Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 24
- 238000002083 X-ray spectrum Methods 0.000 description 14
- WOKWRTYYPDBXRY-UHFFFAOYSA-N sodium;1,3-thiazolidine-2,4-dione Chemical compound [Na].O=C1CSC(=O)N1 WOKWRTYYPDBXRY-UHFFFAOYSA-N 0.000 description 12
- 238000002329 infrared spectrum Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 150000001467 thiazolidinediones Chemical class 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VVNGXLBYKHTCHK-UHFFFAOYSA-N COC1=CC(=NC=N1)N(CCOC1=CC=C(CC2CNCS2)C=C1)C Chemical compound COC1=CC(=NC=N1)N(CCOC1=CC=C(CC2CNCS2)C=C1)C VVNGXLBYKHTCHK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CFVSUEWXOBAYKD-UHFFFAOYSA-N [Na].C1=NC(OC)=CC(N(C)CCOC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)=N1 Chemical compound [Na].C1=NC(OC)=CC(N(C)CCOC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)=N1 CFVSUEWXOBAYKD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200100273A ES2174748B1 (es) | 2001-01-31 | 2001-01-31 | Nueva sal de tiazolidindiona y sus polimorfos como agentes antidiabeticos y procedimiento para la obtencion de los mismos. |
| PCT/IB2002/000229 WO2002060899A1 (en) | 2001-01-31 | 2002-01-21 | New salt of thiazolidinedione and its polymorphs as antidiabetic agents and method for obtaining them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK9552003A3 true SK9552003A3 (en) | 2004-05-04 |
Family
ID=8496644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK955-2003A SK9552003A3 (en) | 2001-01-31 | 2002-01-21 | New salt of thiazolidinedione and its polymorphs as antidiabetic agents and method for obtaining them |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20040106632A1 (bg) |
| EP (1) | EP1355908A1 (bg) |
| JP (1) | JP2004529870A (bg) |
| KR (1) | KR20030078893A (bg) |
| CN (1) | CN1694881A (bg) |
| AP (1) | AP1281A (bg) |
| AR (1) | AR042584A1 (bg) |
| BG (1) | BG108047A (bg) |
| BR (1) | BR0206850A (bg) |
| CA (1) | CA2436556A1 (bg) |
| CZ (1) | CZ20032015A3 (bg) |
| EA (1) | EA200300842A1 (bg) |
| EE (1) | EE200300356A (bg) |
| ES (1) | ES2174748B1 (bg) |
| HU (1) | HUP0302871A2 (bg) |
| IL (1) | IL157028A0 (bg) |
| IS (1) | IS6896A (bg) |
| MA (1) | MA26988A1 (bg) |
| MX (1) | MXPA03006722A (bg) |
| NO (1) | NO20033375L (bg) |
| NZ (1) | NZ527677A (bg) |
| PE (1) | PE20020969A1 (bg) |
| PL (1) | PL362527A1 (bg) |
| SK (1) | SK9552003A3 (bg) |
| WO (1) | WO2002060899A1 (bg) |
| YU (1) | YU60303A (bg) |
| ZA (1) | ZA200305873B (bg) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0842925A1 (en) * | 1987-09-04 | 1998-05-20 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| CN1183130C (zh) * | 1999-09-24 | 2005-01-05 | 中国人民解放军军事医学科学院毒物药物研究所 | 噻唑烷类衍生物及其医药用途 |
| ES2156574B1 (es) * | 1999-11-18 | 2002-02-01 | Vita Invest Sa | Nuevos derivados de tiazolidindiona como agentes antidiabeticos |
-
2001
- 2001-01-31 ES ES200100273A patent/ES2174748B1/es not_active Expired - Fee Related
-
2002
- 2002-01-21 US US10/470,980 patent/US20040106632A1/en not_active Abandoned
- 2002-01-21 KR KR10-2003-7009880A patent/KR20030078893A/ko not_active Application Discontinuation
- 2002-01-21 WO PCT/IB2002/000229 patent/WO2002060899A1/en not_active Application Discontinuation
- 2002-01-21 MX MXPA03006722A patent/MXPA03006722A/es not_active Application Discontinuation
- 2002-01-21 EA EA200300842A patent/EA200300842A1/ru unknown
- 2002-01-21 PL PL02362527A patent/PL362527A1/xx not_active Application Discontinuation
- 2002-01-21 BR BR0206850-8A patent/BR0206850A/pt not_active IP Right Cessation
- 2002-01-21 CN CNA028043863A patent/CN1694881A/zh active Pending
- 2002-01-21 CA CA002436556A patent/CA2436556A1/en not_active Abandoned
- 2002-01-21 EP EP02716216A patent/EP1355908A1/en not_active Withdrawn
- 2002-01-21 HU HU0302871A patent/HUP0302871A2/hu unknown
- 2002-01-21 ZA ZA200305873A patent/ZA200305873B/en unknown
- 2002-01-21 JP JP2002561467A patent/JP2004529870A/ja active Pending
- 2002-01-21 NZ NZ527677A patent/NZ527677A/en unknown
- 2002-01-21 CZ CZ20032015A patent/CZ20032015A3/cs unknown
- 2002-01-21 IL IL15702802A patent/IL157028A0/xx unknown
- 2002-01-21 SK SK955-2003A patent/SK9552003A3/sk not_active Application Discontinuation
- 2002-01-21 EE EEP200300356A patent/EE200300356A/xx unknown
- 2002-01-21 AP APAP/P/2003/002832A patent/AP1281A/en active
- 2002-01-21 YU YU60303A patent/YU60303A/sh unknown
- 2002-01-24 PE PE2002000054A patent/PE20020969A1/es not_active Application Discontinuation
- 2002-01-28 AR ARP020100291A patent/AR042584A1/es not_active Application Discontinuation
-
2003
- 2003-07-28 IS IS6896A patent/IS6896A/is unknown
- 2003-07-28 NO NO20033375A patent/NO20033375L/no not_active Application Discontinuation
- 2003-07-31 MA MA27262A patent/MA26988A1/fr unknown
- 2003-08-01 BG BG108047A patent/BG108047A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP1281A (en) | 2004-05-25 |
| ZA200305873B (en) | 2004-07-30 |
| YU60303A (sh) | 2006-05-25 |
| BG108047A (bg) | 2004-08-31 |
| BR0206850A (pt) | 2004-01-13 |
| EA200300842A1 (ru) | 2004-04-29 |
| ES2174748B1 (es) | 2003-09-16 |
| NZ527677A (en) | 2005-01-28 |
| WO2002060899A1 (en) | 2002-08-08 |
| MA26988A1 (fr) | 2004-12-20 |
| NO20033375L (no) | 2003-08-22 |
| CZ20032015A3 (cs) | 2004-02-18 |
| US20040106632A1 (en) | 2004-06-03 |
| EP1355908A1 (en) | 2003-10-29 |
| MXPA03006722A (es) | 2004-10-15 |
| ES2174748A1 (es) | 2002-11-01 |
| AP2003002832A0 (en) | 2003-09-30 |
| CN1694881A (zh) | 2005-11-09 |
| NO20033375D0 (no) | 2003-07-28 |
| IL157028A0 (en) | 2004-02-08 |
| PE20020969A1 (es) | 2002-12-04 |
| EE200300356A (et) | 2003-10-15 |
| PL362527A1 (en) | 2004-11-02 |
| IS6896A (is) | 2003-07-28 |
| JP2004529870A (ja) | 2004-09-30 |
| KR20030078893A (ko) | 2003-10-08 |
| HUP0302871A2 (hu) | 2003-12-29 |
| AR042584A1 (es) | 2005-06-29 |
| CA2436556A1 (en) | 2002-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0193256B1 (en) | Thiazolidinedione derivatives, their production and use | |
| SK13302002A3 (sk) | V podstate nehydratovaná a nehygroskopická alebo iba mierne hygroskopická hydrochloridová soľ 5-[4-[2-(N-metyl-N-(2- pyridyl)amino) etoxy]benzyl]tiazolidín-2,4-diónu, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie | |
| CA2195559A1 (en) | Thiazolidinedione derivatives, their production and use | |
| EP1173435B1 (en) | Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt | |
| EP3841093A1 (en) | Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors | |
| WO2006082107A1 (de) | Thiazolidinone als inhibitoren der polo like kinase (plk) als arzneimittel | |
| WO2009102226A1 (en) | Malonic acid salt of 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- 2,4-thiazolidinedione | |
| OA11871A (en) | Novel pharmaceutical. | |
| SK14932001A3 (sk) | Polymorfná forma 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoxy] benzyl]tiazolidín-2,4-diónu s kyselinou maleínovou, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie | |
| SK9552003A3 (en) | New salt of thiazolidinedione and its polymorphs as antidiabetic agents and method for obtaining them | |
| EP0702015B1 (en) | Bicyclic oxazole and thiazole substituted ethers | |
| AU2002226609A1 (en) | New salt of thiazolidinedione and its polymorphs as antidiabetic agents and method for obtaining them | |
| OA12492A (en) | New salt of thiazolidinedione and its polymorphs as antidiabetic agents and method for obtaining them. | |
| SK3782003A3 (en) | Sodium salts of 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione | |
| CZ2003849A3 (cs) | Derivát thiazolidindionu a jeho použití jako antidiabetika | |
| DE102004061503A1 (de) | Metasubstituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel | |
| CZ2004844A3 (cs) | Sul kyseliny stavelové s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionu azpusob její prípravy a její pouzití |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |